Phase I, Open-Label, Single-sequence, Cross-Over Study of the Effect of Multiple Doses of Carbamazepine on Single-Dose Tepotinib Pharmacokinetics in Healthy Participants
Latest Information Update: 14 Mar 2024
At a glance
- Drugs Tepotinib (Primary) ; Carbamazepine
- Indications Colorectal cancer; Liver cancer; Non-small cell lung cancer; Solid tumours
- Focus Pharmacokinetics
- Sponsors Merck KGaA
Most Recent Events
- 24 Mar 2023 Results assessing the impact of the strong CYP3A4 inhibitor and P-gp inhibitor itraconazole (200 mg QD as capsules, N=18, NCT05203822), and of the CYP/P-gp inducer carbamazepine (titrated up to 300 mg BID, N=18, NCT05213481) on the pharmacokinetics of single 450 mg doses of tepotinib, presented at the 124th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics.
- 05 Jun 2022 Status changed from active, no longer recruiting to completed.
- 16 Feb 2022 Status changed from recruiting to active, no longer recruiting.